U.S., Sept. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07830940) titled 'Finerenone and Cardiac Remodeling in HFpEF' on Sept. 15.
Brief Summary: This prospective randomized study aims to evaluate the efficacy of Finerenone as add-on therapy to standard of care compared to standard of care alone in preventing heart failure worsening and preserving cardiac function assessed by left ventricular strain in patients with heart failure with preserved ejection fraction.
Study Start Date: Sept. 20
Study Type: INTERVENTIONAL
Condition:
Heart Failure With Preserved Ejection Fraction
Intervention:
DRUG: Finerenone
Non-steroidal mineralocorticoid receptor antagonist 10 to 20 mg orally once daily for 6 months ...